The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Lisinopril is neutral to insulin sensitivity and serum lipoproteins in essential hypertensive patients
To investigate the effects of antihypertensive treatment with the angiotensin-converting enzyme ( ACE ) inhibitor lisinopril on insulin sensitivity and related metabolic variables , the insulin sensitivity index ( SI ) , determined with the Minimal Model Method of Bergman , fasting plasma insulin and glucose concentrations , serum total triglyceride and lipoprotein cholesterol fractions , and blood pressure were assessed in 24 lean , non-diabetic patients with essential hypertension . Following a double-blind , r and omised crossover design , these parameters were measured after a 4-week run-in period , after 8 weeks of lisinopril or placebo , and after an additional 8 weeks on placebo or lisinopril , respectively . Furthermore , the level of physical fitness was estimated using the Conconi bicycle ergometer test . SI was low in this study population ( 5.6 vs 13.3 · 10−4·min−1·mU−1·1−1 in normal lean control subjects ) . It did not differ between the placebo run-in phase , the lisinopril phase , and the placebo crossover phase ( 5.8 , 5.5 , and 5.4·10−4·min−1·mU−1·1−1 , respectively ) . Moreover , during the administration of lisinopril , no significant changes occurred in fasting plasma insulin and glucose , areas under the glucose and insulin curves , glucose disappearance rate , serum total triglycerides , and cholesterol or lipoprotein cholesterol fractions . Heart rate at rest , body weight , and anaerobic threshold remained stable throughout the study . Compliance assessed by pill-counting exceeded 90 % at all visits . These findings demonstrate that the ACE inhibitor lisinopril is neutral with regard to insulin sensitivity , plasma insulin and glucose , and lipoprotein metabolism in patients with essential hypertension
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .